Business
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power
About this update from Quince Therapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nQuince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology.\n\n\n“A-T is a rare pediatric disease with unmet medical need and no approved therapeutic treatment. This post-hoc analysis of patients with A-T treated for a minimum of 24 months in a Phase 3 clinical trial (ATTeST) and an open label extension study, provides data supporting the potential to deliver dexamethasone sodium phosphate encapsulated in a patient’s own red blood cells using our EryDex System without the chronic debilitating toxicities observed with standard corticosteroid treatment,” said Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer. “Adverse events typically observed with prolonged corticosteroid use such as Cushingoid features, weight gain, hypertension, hirsutism, diabetes, or stunted growth were rarely reported in these studies. With more than 6,000 monthly doses administered to nearly 400 patients over the last 10-plus years, we are building a strong safety database as our pivotal Phase 3 clinical trial (NEAT) and its open label extension study continue.”\n\n\nFrontiers in Neurology Publication Highlights\n\n\nThe Frontiers in Neurology publication entitled Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with Ataxia-Telangiectasia describes the safety of long-term use of EryDex in treatment of pediatric patients with A-T.\n\n\nHighlights include:\n\n\n\nEryDex is dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes that has been developed in an effort to address chronic steroid toxicity while maintaining efficacy.\n\n\n\n\nResults include analyses of data from patients with A-T treated with EryDex for a minimum of 24 months.\n\n\n\n\nAnalyses included treatment-emergent and treatment-related adverse events, serious adverse events, and adverse events of special interest.\n\n\n\n\nThe most common treatment-related adverse event was transient infusion-related pruritus, which is the most common steroid related side e...